MA30671B1 - Vaccins contre le paludisme - Google Patents

Vaccins contre le paludisme

Info

Publication number
MA30671B1
MA30671B1 MA31672A MA31672A MA30671B1 MA 30671 B1 MA30671 B1 MA 30671B1 MA 31672 A MA31672 A MA 31672A MA 31672 A MA31672 A MA 31672A MA 30671 B1 MA30671 B1 MA 30671B1
Authority
MA
Morocco
Prior art keywords
protein
particle
hepatitis
antigen
vaccines against
Prior art date
Application number
MA31672A
Other languages
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Christian F Ockenhouse
Anjali Yadava
Original Assignee
Glaxosmithkline Biolog Sa
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1A external-priority patent/GB0614254D0/en
Priority claimed from GB0614476A external-priority patent/GB0614476D0/en
Priority claimed from GB0614473A external-priority patent/GB0614473D0/en
Priority claimed from GB0615115A external-priority patent/GB0615115D0/en
Application filed by Glaxosmithkline Biolog Sa, Us Army filed Critical Glaxosmithkline Biolog Sa
Publication of MA30671B1 publication Critical patent/MA30671B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une particule lipoprotéique innovante, des procédés de préparation et de purification de celle-ci, son utilisation en médecine, en particulier pour la prévention des infections paludéennes, des compositions/vaccins contenant la particule ou des anticorps contre la particule protéique tels que des anticorps monoclonaux ou polyclonaux et leur utilisation, en particulier dans des buts thérapeutiques. L'invention concerne en particulier une particule protéique immunogène qui comprend les monomères suivants: (a) une protéine de fusion comprenant des séquences dérivées d'une protéine CS de P. vivax et de l'antigène S de l'hépatite B (CSV-S), et (b) une protéine de fusion comprenant des séquences dérivées d'une protéine CS de P. falciparum et de l'antigène S de l'hépatite B (RTS), et (c) facultativement l'antigène S dérivé de l'hépatite B.
MA31672A 2006-07-18 2009-02-27 Vaccins contre le paludisme MA30671B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0614254.1A GB0614254D0 (en) 2006-07-18 2006-07-18 Vaccine
GB0614476A GB0614476D0 (en) 2006-07-20 2006-07-20 Vaccine
GB0614473A GB0614473D0 (en) 2006-07-20 2006-07-20 Vaccines
GB0615115A GB0615115D0 (en) 2006-07-28 2006-07-28 Vaccines

Publications (1)

Publication Number Publication Date
MA30671B1 true MA30671B1 (fr) 2009-08-03

Family

ID=38957130

Family Applications (2)

Application Number Title Priority Date Filing Date
MA31671A MA30670B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme
MA31672A MA30671B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA31671A MA30670B1 (fr) 2006-07-18 2009-02-27 Vaccins contre le paludisme

Country Status (22)

Country Link
US (2) US9592282B2 (fr)
EP (2) EP2040742B1 (fr)
JP (2) JP5592110B2 (fr)
KR (2) KR20090092752A (fr)
AR (1) AR061894A1 (fr)
AU (2) AU2007276217B2 (fr)
BR (2) BRPI0714326A2 (fr)
CA (2) CA2657353A1 (fr)
CO (2) CO6150187A2 (fr)
CR (2) CR10561A (fr)
EA (2) EA200900033A1 (fr)
ES (2) ES2437082T3 (fr)
IL (2) IL196410A0 (fr)
MA (2) MA30670B1 (fr)
MX (2) MX2009000650A (fr)
NO (2) NO20090178L (fr)
NZ (2) NZ574238A (fr)
PE (1) PE20080428A1 (fr)
SG (2) SG173363A1 (fr)
TW (1) TW200819462A (fr)
WO (2) WO2008009652A2 (fr)
ZA (1) ZA200900386B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
CA2657353A1 (fr) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccins contre le paludisme
CA2707245A1 (fr) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccin
EP2234638A1 (fr) 2007-12-24 2010-10-06 GlaxoSmithKline Biologicals SA Vaccins contre la malaria
BRPI0919245A2 (pt) * 2008-09-24 2021-11-03 Us Gov Sec Army Vacina para malária
WO2010060719A1 (fr) 2008-11-03 2010-06-03 Crucell Holland B.V. Procédé pour la production de vecteurs adénoviraux
US8784832B2 (en) 2011-08-19 2014-07-22 University Of South Florida (A Florida Non-Profit Corporation) Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US9580482B2 (en) 2012-02-17 2017-02-28 Children's Medical Center Corporation Conformation-stabilized TRAP antigens
EP2945649B1 (fr) 2013-01-22 2018-12-12 Oxford University Innovation Limited Composition et ses applications
EP3213638A1 (fr) 2016-03-01 2017-09-06 Coöperatie Avebe U.A. Analogue de fromage vegan
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
EP3551222B1 (fr) 2016-12-07 2024-08-07 GlaxoSmithKline Biologicals SA Procede de fabrication d'une composition de liposome comprenant une saponine
EP3559669A4 (fr) * 2016-12-23 2020-11-18 The Walter and Eliza Hall Institute of Medical Research Système, procédé, appareil et test de diagnostic pour plasmodium vivax

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3650242T2 (de) * 1985-07-12 1995-06-14 Univ New York Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen.
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
US4997647A (en) * 1987-03-30 1991-03-05 New York University Vaccine against the sporozoite stage of malaria
WO1988009797A1 (fr) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4977647A (en) * 1989-10-27 1990-12-18 D.B. Industries, Inc. Double locking snap hook
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2123612C (fr) 1991-11-16 2002-06-25 Michel De Wilde Proteine hybride entre la proteine cs de plasmodium et l'antigene de surface du virus de l'hepatite b
CA2138997C (fr) 1992-06-25 2003-06-03 Jean-Paul Prieels Composition vaccinale qui contient des adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
CA2171193A1 (fr) * 1993-09-10 1995-03-16 Kim Lee Sim Domaines de fixation provenant de proteines liantes d'erythrocytes de plasmodium vivax et de plasmodium falciparum
JP3967769B2 (ja) 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US20030133944A1 (en) 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US7157092B1 (en) 1998-06-30 2007-01-02 Om Pharma Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
KR20000020497A (ko) 1998-09-21 2000-04-15 임채승 말라리아의 검출방법
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
WO2001034188A1 (fr) * 1999-11-12 2001-05-17 University Of Hawaii Vaccin contre la malaria
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
EP1201250A1 (fr) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
CZ304169B6 (cs) 2001-06-22 2013-12-04 The Wistar Institute Of Anatomy And Biology Replikacne defektní opicí adenovirový vektor, zpusob jeho prípravy a lécivo, imunogenní kompozice a vakcína obsahující rekombinantní adenovirus
EP2277533B1 (fr) 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methodes de vaccination contre le paludisme
WO2004055187A1 (fr) 2002-12-17 2004-07-01 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
WO2004113369A1 (fr) 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh Nouvelle variante de la proteine de surface (hbsag-) du virus de l'hepatite b
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US20050233435A1 (en) * 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
AU2006214694B2 (en) * 2005-01-18 2011-09-08 Walter Reed Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CA2657353A1 (fr) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccins contre le paludisme
EP2234638A1 (fr) * 2007-12-24 2010-10-06 GlaxoSmithKline Biologicals SA Vaccins contre la malaria

Also Published As

Publication number Publication date
CA2657353A1 (fr) 2008-01-24
AU2007276219B2 (en) 2013-10-03
BRPI0714326A2 (pt) 2013-05-07
PE20080428A1 (es) 2008-05-15
NZ574238A (en) 2012-02-24
KR20090092752A (ko) 2009-09-01
ES2437082T3 (es) 2014-01-08
US9592282B2 (en) 2017-03-14
AU2007276217A1 (en) 2008-01-24
EP2040742A2 (fr) 2009-04-01
WO2008009652A2 (fr) 2008-01-24
JP2009543569A (ja) 2009-12-10
EA200900033A1 (ru) 2009-12-30
AR061894A1 (es) 2008-10-01
EP2040743B1 (fr) 2013-10-02
NZ574239A (en) 2011-12-22
CA2657279A1 (fr) 2008-01-24
KR20090094213A (ko) 2009-09-04
WO2008009650A3 (fr) 2008-04-10
CR10561A (es) 2009-04-29
WO2008009652A3 (fr) 2008-05-08
AU2007276217B2 (en) 2013-08-29
US20100150998A1 (en) 2010-06-17
CR10555A (es) 2009-04-29
WO2008009650A2 (fr) 2008-01-24
BRPI0715581A2 (pt) 2013-04-24
AU2007276219A1 (en) 2008-01-24
US9364525B2 (en) 2016-06-14
US20100062028A1 (en) 2010-03-11
ES2525732T3 (es) 2014-12-29
JP2009543846A (ja) 2009-12-10
CO6150189A2 (es) 2010-04-20
NO20090177L (no) 2009-02-16
NO20090178L (no) 2009-02-09
MX2009000650A (es) 2009-07-02
EP2040742B1 (fr) 2014-10-29
MX2009000655A (es) 2009-07-02
IL196410A0 (en) 2011-08-01
TW200819462A (en) 2008-05-01
JP5592110B2 (ja) 2014-09-17
JP5222289B2 (ja) 2013-06-26
EP2040743A2 (fr) 2009-04-01
IL196471A0 (en) 2011-08-01
SG173363A1 (en) 2011-08-29
SG173377A1 (en) 2011-08-29
ZA200900386B (en) 2014-03-26
MA30670B1 (fr) 2009-08-03
EA200900032A1 (ru) 2011-02-28
CO6150187A2 (es) 2010-04-20
AU2007276217A8 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MA30670B1 (fr) Vaccins contre le paludisme
Wright et al. Plasmodium falciparum erythrocyte invasion: combining function with immune evasion
Castellanos-Gonzalez et al. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis
Radocha et al. Monoclonal antibodies and antibody drug conjugates in multiple myeloma
Healer et al. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum
Taechalertpaisarn et al. Biochemical and functional analysis of two Plasmodium falciparum blood-stage 6-cys proteins: P12 and P41
MA30359B1 (fr) Composition pharmaceutique a liberation prolongee sur la base d'un systeme de liberation comprenant un polymere soluble dans l'acide et un polymere dependant du ph
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
Kengne-Ouafo et al. Immune responses to the sexual stages of Plasmodium falciparum parasites
EP1450857A4 (fr) Anticorps de neutralisation a activite sensiblement croisee contre le virus vih selectionnes a l'aide de complexes de co-recepteurs de env-cd4
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
MA32030B1 (fr) Vaccins anti-malaria
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA27699A1 (fr) Vaccin contre vhc
MA32821B1 (fr) Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)
Atcheson et al. A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development
Vigdorovich et al. Coimmunization with preerythrocytic antigens alongside circumsporozoite protein can enhance sterile protection against Plasmodium Sporozoite infection
Ouédraogo et al. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
Mehrizi et al. Th1 immune response to Plasmodium falciparum recombinant thrombospondin‐related adhesive protein (TRAP) antigen is enhanced by TLR3‐specific adjuvant, poly (I: C) in BALB/c mice
Pourhashem et al. Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.